Hormone receptor positive metastatic breast cancer
Clinical trials for Hormone receptor positive metastatic breast cancer explained in plain language.
Never miss a new study
Get alerted when new Hormone receptor positive metastatic breast cancer trials appear
Sign up with your email to follow new studies for Hormone receptor positive metastatic breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a walking routine delay resistance to breast cancer therapy?
Disease control OngoingThis phase 1 trial tests whether a personalized aerobic exercise program, including supervised walking sessions done remotely, can be safely added to the usual first-line hormone therapy for metastatic breast cancer. Researchers want to see if exercise helps delay the development…
Matched conditions: HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Higher dose of breast cancer drug faslodex tested in new trial
Disease control OngoingThis phase 2 trial is testing a higher dose (500 mg) of the hormone therapy fulvestrant (Faslodex) as a first treatment for postmenopausal women with hormone receptor positive metastatic breast cancer. The study aims to see if this higher dose improves clinical benefit rates comp…
Matched conditions: HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER
Phase 2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Genetic clues may reveal why some breast cancers resist treatment
Knowledge-focused OngoingThis study is investigating whether genetic changes in tumor tissue and blood can predict how well people with hormone receptor-positive metastatic breast cancer respond to a combination of endocrine therapy and palbociclib. Researchers will collect tumor samples and blood from p…
Matched conditions: HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC